KarMMa-3
Ide-cel tripled progression-free time versus standard regimens in heavily pretreated myeloma, but did not clearly extend life after most control patients crossed over.
PFS 13.3 vs 4.4 months (HR 0.49); ORR 71% vs 42%. OS HR 1.01 unadjusted; crossover-adjusted analyses favour ide-cel. Approved ≥2 lines April 2024.
- Median 13.3 vs 4.4 months with Ide-cel compared with Standard regimens; about 8.9 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 51 percent lower chance of the event at any given time (hazard ratio 0.49, likely range 0.38 to 0.65).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Triple-class-exposed myeloma after 2-4 prior lines: ide-cel vs standard regimens. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- Key paperCARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy
Shares KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, Multiple myeloma.
- TargetBCMA
Shares Idecabtagene vicleucel, KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, Multiple myeloma.
- TermICANS (neurotoxicity)
Shares Idecabtagene vicleucel, Multiple myeloma.
- TermCytokine release syndrome (CRS)
Shares Idecabtagene vicleucel, KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, Multiple myeloma.
- CompanyBristol Myers Squibb
Shares Idecabtagene vicleucel, KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma, Multiple myeloma.